ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2023
A comprehensive review on potential applications of metallic nanoparticles as antifungal therapies to combat human fungal diseases.
Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 57 citations in OpenAlex.
- Recent Advances in Gold Nanoparticles as Antimicrobial Agents Against Pathogenic Bacteria: A Review (2022-2026).Applied biochemistry and biotechnology · 2026Review
- Chitosan-Loaded Inorganic Oxide Nanocomposites (SiOFoods (Basel, Switzerland) · 2026Article
- Biogenic Synthesis, Structural Characterization, and Biological Evaluation of Nanoparticles Derived fromNanomaterials (Basel, Switzerland) · 2026Article
- Ni-Fe Nanoparticles fromCurrent pharmaceutical design · 2026Article
- Phytogenic synthesis of copper nanoparticles by using leaf extract of Eucalyptus globulus and its antifungal activity against Fusarium oxysporum and Fusarium Solani.BMC plant biology · 2025Article
- Comprehensive insights into the role of nanocarriers in advancing azole-based ocular therapeutics.RSC advances · 2025Review
- Protective effect of histatin 5 and amphotericin B conjugated nanostructures in C. albicans challenged Swiss albino mice.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Review
- Promising biomedical applications using superparamagnetic nanoparticles.European journal of medical research · 2025Review
- Functionalized Silver Nanoparticles as Multifunctional Agents Against Gut Microbiota Imbalance and Inflammation.Nanomaterials (Basel, Switzerland) · 2025Article
- Nanoparticles as New Antifungals in the Prevention of Bovine MycoticMolecules (Basel, Switzerland) · 2025Article
- One-Pot Synthesis and Characterization of Magnetic α-FeChemistryOpen · 2025Article
- Advancing cryptococcal treatment: The role of nanoparticles in mitigating antifungal resistance.Current research in microbial sciences · 2025Review
- Article
- Advances in Metal and Metal Oxide Nanomaterials for Topical Antimicrobial Applications: Insights and Future Perspectives.Molecules (Basel, Switzerland) · 2024Review
- Advancements in the nanodelivery of azole-based fungicides to control oil palm pathogenic fungi.Heliyon · 2024Review
- Green synthesis of silver and gold-doped zinc oxide nanocomposite with propolis extract for enhanced anticancer activity.Scientific reports · 2024Article
- The progress and future of the treatment of Candida albicans infections based on nanotechnology.Journal of nanobiotechnology · 2024Review
- Novel composite of nano zinc oxide and nano propolis as antibiotic for antibiotic-resistant bacteria: a promising approach.Scientific reports · 2024Article
- Biochemical Behavior, Influence on Cell DNA Condition, and Microbiological Properties of Wool and Wool-Copper Materials.Materials (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human pathogenic fungi are responsible for causing a range of infection types including mucosal, skin, and invasive infections. Life-threatening and invasive fungal infections (FIs) are responsible for mortality and morbidity, especially for individuals with compromised immune function. The number of currently available therapeutic agents against invasive FIs is limited compared to that against bacterial infections. In addition, the increased mortality and morbidity caused by FIs are linked to the limited number of available antifungal agents, antifungal resistance, and the increased toxicity of these agents. Currently available antifungal agents have several drawbacks in efficiency, efficacy, toxicity, activity spectrum, and selectivity. It has already been demonstrated with numerous metallic nanoparticles (MNPs) that these nanoparticles can serve as an effective and alternative solution as fungicidal agents. MNPs have great potential owing to their intrinsic antifungal properties and potential to deliver antifungal drugs. For instance, gold nanoparticles (AuNPs) have the capacity to disturb mitochondrial calcium homeostasis induced AuNP-mediated cell death in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.